Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Rachel Altshuler, Ph.D.
Principal Investigator
Bin Duan
Awardee Organization

University Of Nebraska Medical Center
United States

Fiscal Year
2025
Activity Code
R21
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date
NIH RePORTER
For more information, see NIH RePORTER Project 1R21CA298918-01

Flupirtine Analogue Synthesis and Screening for the Treatment of Chemotherapy-Induced Neuropathic Pain

Chemotherapy-induced neuropathic pain (CINP) is a common side effect for cancer patients and can greatly reduce patients’ quality of life. Although a wide range of pharmacological agents have been investigated in clinical trials as potential CINP therapies, currently approved analgesics for neuropathic pain are inadequate and offer limited beneficial effects in ameliorating CINP. Flupirtine, a non-opioid and non-steroidal antiinflammatory drug analgesic, can effectively relieve various pain conditions in clinical studies. However, safety concerns, particularly rare but severe liver toxicity, led to restrictions on its use and eventual withdrawal from the market in the U.S. The adverse side effects of flupirtine that induce hepatotoxicity have been shown to not be linked with the primary antinociceptive mechanism of action. We have developed a flupirtine analogue library and demonstrated that one of the compounds (compound 5) had a much faster metabolism rate than the flupirtine parent and did not induce hepatotoxicity after intraperitoneal injection. We have also successfully developed both short-term and long-term mouse CINP models. Our results showed that compound 5 effectively ameliorated short-term CINP, as evidenced by various pain behavior tests. In this proposal, we will further synthesize and screen flupirtine analogues through structural modification to enhance their liver safety profile while maintaining or even improving therapeutic efficacy to effectively relieve CIPN. The specific aims of the studies are (1) to strategically develop potent Kv7.2/7.3 activators unable to form hepatotoxic metabolites, (2) to determine the analgesic efficacies of flupirtine analogues in the CINP mouse models. This proposal will develop a series of novel flupirtine analogues with reduced or eliminated hepatotoxicity as non-opioid analgesics to relieve CINP and treat various other pain conditions and non-pain-related diseases.